Search
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.
Daunorubicin
go.drugbank.com/drugs/DB00694ApprovedInvestigationalA very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnof EGFR. … Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15520ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 MLGaretosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic
Sodium stibogluconate
go.drugbank.com/drugs/DB05630ApprovedInvestigationalWidespread resistance has limited the utility of sodium stibogluconate, and in many parts of the world, amphotericin or miltefosine are used instead. … It belongs to the class of medicines known as the pentavalent antimonials. Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline).
Synonyms: Antimony (V) derivative of sodium gluconate, Stibogluconate de sodiumArmodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalapnea (OSA), narcolepsy, or shift work disorder (SWD). … Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil.
Categories: Metabolic Side Effects of Drugs and SubstancesValproate bismuth
go.drugbank.com/drugs/DB13910ApprovedValproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCyromazine
go.drugbank.com/drugs/DB20549ExperimentalCyromazine has a monoisotopic molecular weight of 166.1 Da.
Categories: Compounds used in a research, industrial, or household settingAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000] … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.